Gillson Sciences, a leader in analytical laboratory testing and scientific solutions, announced their partnership with SanAir ...

As many people begin the year with health and fitness resolutions, Boise State University’s Human Performance Laboratory is ...

95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s robotics platform grows thousands of human tissues daily, directly tackling the biological gap behind ...

PHILADELPHIA--(BUSINESS WIRE)--Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed ...

Function Health, a preventive health and longevity startup, acquired Ezra to integrate Function’s lab testing capabilities with the company’s artificial-intelligence-powered full-body scans, combining ...

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise, their toxicity to healthy tissue remains a major hurdle.

Find out how scientists are maximizing retinal organoid effectiveness to sustain critical retinal ganglion cells.

Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials. Only about 10% of drugs in development ever make it to market.

Andrei Georgescu, PhD, CEO of Vivodyne, was hoping to couple his interests in science and engineering when he chose UPenn for his graduate research. His goal was to build on his background in ...